Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

44.60 +0.32 (+0.72%)
Streaming Delayed Price Updated: 12:14 PM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
21 22 Next >
News headline image
Earnings Preview For Exelixis ↗
 
Via Benzinga
News headline image
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition. ↗
NASDAQ:EXEL, a growth stock which is not overvalued. 
Via Chartmill
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
From Exelixis, Inc.
Via Business Wire
News headline image
Breaking Down Exelixis: 7 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
From Exelixis, Inc.
Via Business Wire
News headline image
NASDAQ:EXEL is showing good growth, while it is not too expensive. ↗
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
6 Analysts Have This to Say About Exelixis ↗
 
Via Benzinga
News headline image
NASDAQ:EXEL, a growth stock which is not overvalued. ↗
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL. 
Via Chartmill
News headline image
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
From Exelixis, Inc.
Via Business Wire
News headline image
Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study ↗
Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 ↗
These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024. 
Via InvestorPlace
News headline image
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
From Exelixis, Inc.
Via Business Wire
News headline image
3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations. 
Via InvestorPlace
News headline image
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
News headline image
Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified 
Via Benzinga
News headline image
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗
Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? ↗
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an  
Via Benzinga
News headline image
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes ↗
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco. 
Via Investor's Business Daily
News headline image
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
From Arcus Biosciences
Via Business Wire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
News headline image
3 Biotech Stocks With the Strongest Clinical Pipelines ↗
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines. 
Via InvestorPlace
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.